Develops CNS-directed gene therapies for genetically defined neurodegeneration (Alzheimer's, FTD, Parkinson's). Platform targets heterozygous lysosomal enzyme loss-of-function carriers to address distinct Alzheimer’s subpopulations and key disease pathways.